Stack Financial Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Stack Financial Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,000	Closed	-$47K	–	51
2016 Q1	$47K	Hold	10,000	–	–	0.01%	49
2015 Q4	$50K	Hold	10,000	–	–	0.01%	51
2015 Q3	$35K	Buy	+10,000	New	+$67K	﹤0.01%	49

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stack Financial Management's KERX Position: Q2 2016 in Review

Stack Financial Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 10,000 shares — an estimated $47K sold.

Stack Financial Management first reported a position in KERX in Q3 2015 and held it in 3 quarters. The position peaked at $50K in Q4 2015. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

Stack Financial Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Stack Financial Management sold 10,000 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $47K.
Stack Financial Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2015 and held it in 3 quarters.
Stack Financial Management's Keryx Biopharmaceuticals Inc position peaked at $50K in Q4 2015.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Stack Financial Management's 13F filing for Q2 2016, filed 8 Aug 2016.